{
  "docId": "019de075-3c48-75dd-a16f-ddcce5fecf48",
  "docSlug": "20dccf7a034b09514201ed73755b4bbb",
  "documentTitle": "Absci | Investor Presentation Deck | 48 slides",
  "authorId": "absci",
  "authorName": "Absci",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 48,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "The slide uses a case study format to validate the efficacy of the company's AI platform.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-3c48-75dd-a16f-ddcce5fecf48/15",
  "deckHref": "/decks/019de075-3c48-75dd-a16f-ddcce5fecf48",
  "deckJsonHref": "/decks/019de075-3c48-75dd-a16f-ddcce5fecf48.json",
  "deckAnchorHref": "/decks/019de075-3c48-75dd-a16f-ddcce5fecf48#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.22,
        "w": 0.33,
        "x": 0.63,
        "y": 0.42
      },
      "kind": "list",
      "text": "AI designs are specific: Inputting a mis-matched undesired antigen (e.g., Rat HER2, HER3, VEGF) into the model results in significant performance decrease towards desired antigen. Indicates the model's use of antigen information for sequence designs.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f3bb649-a9d0-4002-aa43-5d6e8baff130",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.33,
        "x": 0.63,
        "y": 0.66
      },
      "kind": "list",
      "text": "AI models outperform biological baselines: De novo designed HCDR3s achieve a 4-fold improvement over random OAS baseline. De novo designed HCDR123s achieve an 11-fold improvement over random OAS baseline.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab7cc942-a84c-4551-a8f8-d7284aab0403",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.58,
        "x": 0.04,
        "y": 0.28
      },
      "kind": "table",
      "text": "HER2 Binding Rate (%) measured via ACE assay; HCDR3; HCDR123; Zero-shot de novo generated; Human HER2; 10.6; 1.8; Rat HER2; 2.8; 0.5; HER3; 2.9; 0.2; VEGF; 2.5; 0.0; Biological baseline; OAS; 2.68; 0.16; OAS-J; 5.25; 0.32; SAbDab; 3.16; 0.06; Random baseline; Permuted sequences; 0.33; N/A",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40d676ad-b00e-4f11-8ccf-52a4b2e9401c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "AI designs of all HCDRs achieve high binding rates and outperform biological baselines",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9207d081-205a-4b7e-bc5c-b492475c1bd0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "d833a379-6422-479c-858e-8233955f251c",
      "evidence": "The slide presents a table with data",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 48,
      "from": 6,
      "beatId": "7c165ad6-f743-4405-9aff-e111239d7bcd",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 6-48 present Absci's AI-powered solution for biologic drug creation",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}